Cancer cell-derived IL-1α induces CCL22 and the recruitment of regulatory T cells
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
In cancer patients, immunosuppression through regulatory T cells (Treg) is a crucial component of tumor immune evasion and contributes to disease progression. Tumor-infiltrating Treg in particular suppress local effector T cell responses and are associated with poor prognosis in tumors such as human pancreatic cancer or hepatocellular carcinoma (HCC). The chemokine CCL22 is known to recruit Treg into the tumor tissue and many types of human tumors are known to express high levels of CCL22. The mechanisms leading to intratumoral secretion of CCL22 are so far unknown. We demonstrate here that intratumoral CCL22 is induced in tumor-infiltrating immune cells through cancer cell-derived interleukin-1 (IL-1α). In pancreatic cancer and HCC, CCL22 is produced by intratumoral dendritic cells, while the cancer cells themselves do not secrete CCL22 in vitro and in vivo. Incubation of human peripheral blood mononuclear cells (PBMC) or murine splenocytes with tumor cells or tumor cell supernatants strongly induced CCL22 secretion in vitro. Tumor cell supernatants contained IL-1 and CCL22 induction in PBMC could be specifically prevented by the IL-1 receptor antagonist anakinra or by transfection of tumor cell lines with IL-1 siRNA, leading to a suppression of Treg migration. In conclusion, we identify here tumor cell-derived IL-1α as a major inducer of the Treg attracting chemokine CCL22 in human cancer cells. Therapeutic blockade of the IL-1 pathway could represent a promising strategy to inhibit tumor-induced immunosuppression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science · doi:10.1126/science.1203486 · Cited by 6,474 · cited 1×
“Different mechanisms contribute to the establishment of the tumor-associated immunosuppressive milieu, including the recruitment of suppressive cell populations as well as the secretion and upregulation of inflammatory or inhibitory cytokines and chemokines.(1) The CC-motif ligand 22 (CCL22) is a chemokine which has b…”
BackgroundFu, J., Xu, D., Liu, Z., Shi, M., Zhao, P., Fu, B., Zhang, Z., Yang, H., Zhang, H., Zhou, C., et al. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.102 · Cited by 897 · cited 2×
“and tumor infiltration by Treg was clearly associated with poor clinical outcome.(26) In the present study, we found that the Tregattracting chemokine CCL22 is expressed in the majority of human HCC samples suggesting that CCL22 is involved in the recruitment of Treg to these tumors.”
BackgroundCloned dendritic cells can present exogenous antigens on both MHC class I and class II molecules.
Shen, Z., Reznikoff, G., Dranoff, G., & Rock, K. L. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.158.6.2723 · Cited by 846
Gobert, M., Treilleux, I., Bendriss-Vermare, N., Bachelot, T., Goddard-Leon, S., Arfi, V., Biota, C., Doffin, A. C., Durand, I., Olive, D., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2360 · Cited by 758
Ling, J., Kang, Y., Zhao, R., Xia, Q., Lee, D.-F., Chang, Z., Li, J., Peng, B., Fleming, J. B., Wang, H., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2011.12.006 · Cited by 513
Mizukami, Y., Kono, K., Kawaguchi, Y., Akaike, H., Kamimura, K., Sugai, H., & Fujii, H. (2008) · International Journal of Cancer · doi:10.1002/ijc.23392 · Cited by 374
Faget, J., Biota, C., Bachelot, T., Gobert, M., Treilleux, I., Goutagny, N., Durand, I., Léon-Goddard, S., Blay, J. Y., Caux, C., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0573 · Cited by 129 · cited 1×
“These findings are seemingly contradictory to a former study reporting CCL22 upregulation in human breast cancer cell lines upon culture in PBMC supernatants.(39) This may, however, be explained by the addition of IFNg in incubation protocols of that study, which is known to induce CCL22 in epithelial cells.”
Result
Cited by
The immunology of hepatocellular carcinoma
Ringelhan, M., Pfister, D., O’Connor, T., Pikarsky, E., & Heikenwalder, M. (2018) · Nature Immunology · doi:10.1038/s41590-018-0044-z · Cited by 1,076
Li, C., Jiang, P., Wei, S., Xu, X., & Wang, J. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01234-1 · Cited by 921
Targeting cytokine and chemokine signaling pathways for cancer therapy
Yi, M., Li, T., Niu, M., Zhang, H., Wu, Y., Wu, K., & Dai, Z. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01868-3 · Cited by 455
Acquired resistance to cancer immunotherapy: Role of tumor-mediated immunosuppression
Saleh, R., & Elkord, E. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.07.017 · Cited by 292
Wang, D., Yang, L., Yue, D., Cao, L., Li, L., Wang, D., Ping, Y., Shen, Z., Zheng, Y., Wang, L., et al. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.03.040 · Cited by 183
Metadata
- Authors
- Wiedemann, G. M., Knott, M. M. L., Vetter, V. K., Rapp, M., Haubner, S., Fesseler, J., Kühnemuth, B., Layritz, P., Thaler, R., Kruger, S., Ormanns, S., Mayr, D., Endres, S., & Anz, D.
- Venue
- OncoImmunology
- Publisher
- Informa UK Limited
- Published
- 2016-04-25
- Volume
- 5
- Issue
- 9
- Pages
- e1175794
- ISSN
- 2162-4011 (ISSN-L)
- 2162-402X
- OpenAlex
- W2343759513
- Cited by
- 107
- References
- 7
- FWCI
- 2.63
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cancer cell-derived IL-1α induces CCL22 and the recruitment of regulatory T cells. https://app.cochat.ai/papers/10.1080/2162402x.2016.1175794
- The paper
- Wiedemann, G. M., Knott, M. M. L., Vetter, V. K., Rapp, M., Haubner, S., Fesseler, J., Kühnemuth, B., Layritz, P., Thaler, R., Kruger, S., Ormanns, S., Mayr, D., Endres, S., & Anz, D. (2016). Cancer cell-derived IL-1α induces CCL22 and the recruitment of regulatory T cells. OncoImmunology. https://doi.org/10.1080/2162402x.2016.1175794
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.